Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
ADA 2018 In the long-term Danish Steno 2 study, interventions targeting complications were found to improve disease-free-life length, and costs were not higher than with conventional treatment.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.
Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Clinical updates in management of cardiovascular risk For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.
No consistent benefit was seen of popular supplements (multivitamins, vitamin D, calcium and vitamin C) for the prevention of CVD, myocardial infarction or stroke, or on all-cause mortality.
Clinical updates in management of cardiovascular risk CV risk factors that drive arterial disease in early life have a major impact on future CV risk. Communication about early lifestyle intervention to the public should be a major focus to reduce CV risk in later years.
Based on objective and critical appraisal of the literature on potential adverse effects of statins, the EAS Consensus Panel concludes that statin treatment is remarkably safe.
A multidisciplinary ESC Task Force aimed to give as much practical advice as possible on the most appropriate management and therapy for each of the subtypes of syncope, although trial evidence is scarce.
The potential incremental benefit of PCSK9 inhibition varies a lot among patients with stable CAD, with the greatest benefit observed in younger patients with highest risk factor burden and high LCL-c levels.